{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:22:23Z","timestamp":1790050943913,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-024-03906-2","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T06:19:15Z","timestamp":1736230755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk prediction modeling for cardiorenal clinical outcomes in patients with non-diabetic CKD using US nationwide real-world data"],"prefix":"10.1186","volume":"26","author":[{"given":"Christoph","family":"Wanner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schuchhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Brinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kleinjung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsiana","family":"Vaitsiakhovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"3906_CR1","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","volume":"96","author":"KJ Jager","year":"2019","unstructured":"Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96:1048\u201350.","journal-title":"Kidney Int"},{"key":"3906_CR2","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","volume":"392","author":"KJ Foreman","year":"2018","unstructured":"Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016\u201340 for 195 countries and territories. Lancet. 2018;392:2052\u201390.","journal-title":"Lancet"},{"key":"3906_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"B Bikbov","year":"2020","unstructured":"Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709\u201333.","journal-title":"Lancet"},{"key":"3906_CR4","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389:1238\u201352.","journal-title":"Lancet"},{"key":"3906_CR5","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/ndt\/gfr456","volume":"27","author":"KU Eckardt","year":"2012","unstructured":"Eckardt KU, B\u00e4rthlein B, Baid-Agrawal S, Beck A, Busch M, Eitner F, et al. The German Chronic Kidney Disease (GCKD) study: design and methods. Nephrol Dial Transplant. 2012;27:1454\u201360.","journal-title":"Nephrol Dial Transplant"},{"key":"3906_CR6","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296\u2013305.","journal-title":"N Engl J Med"},{"key":"3906_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2010.483","volume":"80","author":"AS Levey","year":"2011","unstructured":"Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17\u201328.","journal-title":"Kidney Int"},{"key":"3906_CR8","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.kint.2016.09.049","volume":"91","author":"RO Mathew","year":"2017","unstructured":"Mathew RO, Bangalore S, Lavelle MP, Pellikka PA, Sidhu MS, Boden WE, et al. Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review. Kidney Int. 2017;91:797\u2013807.","journal-title":"Kidney Int"},{"key":"3906_CR9","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1001\/jamainternmed.2017.0197","volume":"177","author":"WC Tsai","year":"2017","unstructured":"Tsai WC, Wu HY, Peng YS, Yang JY, Chen HY, Chiu YL, et al. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis. JAMA Intern Med. 2017;177:792\u20139.","journal-title":"JAMA Intern Med"},{"key":"3906_CR10","doi-asserted-by":"publisher","first-page":"147032031880349","DOI":"10.1177\/1470320318803495","volume":"19","author":"F Shunan","year":"2018","unstructured":"Shunan F, Jiqing Y, Xue D. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events in patients with diabetes and overt nephropathy: a meta-analysis of randomised controlled trials. J Renin Angiotensin Aldosterone Syst. 2018;19:1470320318803495.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"3906_CR11","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219\u201329.","journal-title":"N Engl J Med"},{"key":"3906_CR12","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"3906_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2015.03.154","volume":"188","author":"P Ferrero","year":"2015","unstructured":"Ferrero P, Iacovoni A, D\u2019Elia E, Vaduganathan M, Gavazzi A, Senni M. Prognostic scores in heart failure \u2014 critical appraisal and practical use. Int J Cardiol. 2015;188:1\u20139.","journal-title":"Int J Cardiol"},{"key":"3906_CR14","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2215\/CJN.10321014","volume":"10","author":"D Dunkler","year":"2015","unstructured":"Dunkler D, Gao P, Lee SF, Heinze G, Clase CM, Tobe S, et al. Risk prediction for early CKD in type 2 diabetes. Clin J Am Soc Nephrol. 2015;10:1371\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3906_CR15","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/jama.2011.451","volume":"305","author":"N Tangri","year":"2011","unstructured":"Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305:1553\u20139.","journal-title":"JAMA"},{"key":"3906_CR16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.semnephrol.2016.12.004","volume":"37","author":"B Lerner","year":"2017","unstructured":"Lerner B, Desrochers S, Tangri N. Risk prediction models in CKD. Semin Nephrol. 2017;37:144\u201350.","journal-title":"Semin Nephrol"},{"key":"3906_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1053\/j.ajkd.2016.07.030","volume":"69","author":"N Tangri","year":"2017","unstructured":"Tangri N, Inker LA, Hiebert B, Wong J, Naimark D, Kent D, et al. A dynamic predictive model for progression of CKD. Am J Kidney Dis. 2017;69:514\u201320.","journal-title":"Am J Kidney Dis"},{"key":"3906_CR18","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.ekir.2022.05.004","volume":"7","author":"T Ferguson","year":"2022","unstructured":"Ferguson T, Ravani P, Sood MM, Clarke A, Komenda P, Rigatto C, et al. Development and external validation of a machine learning model for progression of CKD. Kidney Int Rep. 2022;7:1772\u201381.","journal-title":"Kidney Int Rep"},{"key":"3906_CR19","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.2337\/dc20-2715","volume":"44","author":"N Stempniewicz","year":"2021","unstructured":"Stempniewicz N, Vassalotti JA, Cuddeback JK, Ciemins E, Storfer-Isser A, Sang Y, et al. Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. health care organizations. Diabetes Care. 2021;44:2000\u20139.","journal-title":"Diabetes Care"},{"key":"3906_CR20","doi-asserted-by":"publisher","first-page":"596","DOI":"10.7326\/0003-4819-158-8-201304160-00004","volume":"158","author":"N Tangri","year":"2013","unstructured":"Tangri N, Kitsios GD, Inker LA, Griffith J, Naimark DM, Walker S, et al. Risk prediction models for patients with chronic kidney disease: a systematic review. Ann Intern Med. 2013;158:596\u2013603.","journal-title":"Ann Intern Med"},{"key":"3906_CR21","doi-asserted-by":"publisher","unstructured":"Lai TS, Tsao HM, Chou YH, Liang SL, Chien KL, Chen YM. A competing risk predictive model for kidney failure in patients with advanced chronic kidney disease. J Formos Med Assoc. 2023: https:\/\/doi.org\/10.1016\/j.jfma.2023.11.010.","DOI":"10.1016\/j.jfma.2023.11.010"},{"key":"3906_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40620-022-01340-x","volume":"36","author":"C Wanner","year":"2023","unstructured":"Wanner C, Schuchhardt J, Bauer C, Lindemann S, Brinker M, Kong SX, et al. Clinical characteristics and disease outcomes in non-diabetic chronic kidney disease: retrospective analysis of a US healthcare claims database. J Nephrol. 2023;36:45\u201354.","journal-title":"J Nephrol"},{"key":"3906_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s44196-024-00685-4","volume":"17","author":"C Bauer","year":"2024","unstructured":"Bauer C, Schuchhardt J, Vaitsiakhovich T, Kleinjung F. Computational and human intelligence methods for constructing practical risk prediction models: An application to cardio-renal outcomes in non-diabetic CKD patients. Int J Comput Intell Syst. 2024;17:276.","journal-title":"Int J Comput Intell Syst"},{"key":"3906_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1109\/MCI.2006.329691","volume":"1","author":"M Dorigo","year":"2006","unstructured":"Dorigo M, Birattari M, St\u00fctzle T. Ant colony optimization. IEEE Comput Intell Mag. 2006;1:28\u201339.","journal-title":"IEEE Comput Intell Mag"},{"key":"3906_CR25","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s12325-020-01568-8","volume":"38","author":"M Murton","year":"2021","unstructured":"Murton M, Goff-Leggett D, Bobrowska A, Garcia Sanchez JJ, James G, Wittbrodt E, et al. Burden of chronic kidney disease by KDIGO categories of glomerular filtration rate and albuminuria: a systematic review. Adv Ther. 2021;38:180\u2013200.","journal-title":"Adv Ther"},{"key":"3906_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2010.165","volume":"8","author":"AL Bui","year":"2011","unstructured":"Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8:30\u201341.","journal-title":"Nat Rev Cardiol"},{"key":"3906_CR27","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","volume":"13","author":"B Ziaeian","year":"2016","unstructured":"Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13:368\u201378.","journal-title":"Nat Rev Cardiol"},{"key":"3906_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cardfail.2003.09.003","volume":"10","author":"ML Hockensmith","year":"2004","unstructured":"Hockensmith ML, Estacio RO, Mehler P, Havranek EP, Ecder ST, Lundgren RA, et al. Albuminuria as a predictor of heart failure hospitalizations in patients with type 2 diabetes. J Card Fail. 2004;10:126\u201331.","journal-title":"J Card Fail"},{"key":"3906_CR29","doi-asserted-by":"publisher","first-page":"665831","DOI":"10.3389\/fcvm.2021.665831","volume":"8","author":"W Liang","year":"2021","unstructured":"Liang W, Liu Q, Wang QY, Yu H, Yu J. Albuminuria and dipstick proteinuria for predicting mortality in heart failure: a systematic review and meta-analysis. Front Cardiovasc Med. 2021;8:665831.","journal-title":"Front Cardiovasc Med"},{"key":"3906_CR30","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1681\/ASN.2014030253","volume":"26","author":"M Sud","year":"2015","unstructured":"Sud M, Tangri N, Pintilie M, Levey AS, Naimark DMJ. ESRD and death after heart failure in CKD. J Am Soc Nephrol. 2015;26:715\u201322.","journal-title":"J Am Soc Nephrol"},{"key":"3906_CR31","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1016\/j.jacc.2019.02.071","volume":"73","author":"N Bansal","year":"2019","unstructured":"Bansal N, Zelnick L, Bhat Z, Dobre M, He J, Lash J, et al. Burden and outcomes of heart failure hospitalizations in adults with chronic kidney disease. J Am Coll Cardiol. 2019;73:2691\u2013700.","journal-title":"J Am Coll Cardiol"},{"key":"3906_CR32","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1053\/j.ajkd.2023.04.014","volume":"82","author":"N Yarandi","year":"2023","unstructured":"Yarandi N, Shirali AC. Onconephrology: Core Curriculum 2023. Am J Kidney Dis. 2023;82:743\u201361.","journal-title":"Am J Kidney Dis"},{"key":"3906_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/pubmed\/fdx026","volume":"40","author":"B Young","year":"2018","unstructured":"Young B, Bedford L, Kendrick D, Vedhara K, Robertson JFR, das Nair R. Factors influencing the decision to attend screening for cancer in the UK: a meta-ethnography of qualitative research. J Public Health (Oxf). 2018;40:315\u201339.","journal-title":"J Public Health (Oxf)"},{"key":"3906_CR34","doi-asserted-by":"publisher","first-page":"e1918169","DOI":"10.1001\/jamanetworkopen.2019.18169","volume":"2","author":"KR Tuttle","year":"2019","unstructured":"Tuttle KR, Alicic RZ, Duru OK, Jones CR, Daratha KB, Nicholas SB, et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. JAMA Netw Open. 2019;2:e1918169.","journal-title":"JAMA Netw Open"},{"key":"3906_CR35","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/pds.4297","volume":"26","author":"ML Berger","year":"2017","unstructured":"Berger ML, Sox H, Willke RJ, Brixner DL, Eichler HG, Goettsch W, et al. Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26:1033\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3906_CR36","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence - what is it and what can it tell us? N Engl J Med. 2016;375:2293\u20137.","journal-title":"N Engl J Med"},{"key":"3906_CR37","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/pds.5398","volume":"31","author":"JM Paik","year":"2022","unstructured":"Paik JM, Patorno E, Zhuo M, Bessette LG, York C, Gautam N, et al. Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data. Pharmacoepidemiol Drug Saf. 2022;31:467\u201375.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03906-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-024-03906-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03906-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T07:04:36Z","timestamp":1736233476000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-024-03906-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3906"],"URL":"https:\/\/doi.org\/10.1186\/s12882-024-03906-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"assertion":[{"value":"20 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data included in the Optum\u00ae CDM database are de-identified and are in compliance with the Health Insurance Portability and Accountability Act of 1996 to preserve participant anonymity and confidentiality, and as such this study followed the principles of the Declaration of Helsinki without the requirement for review from a formal ethics review committee. The use of the provided Optum\u00ae data was determined by the New England Institutional Review Board to not constitute research involving human subjects and was therefore exempt from board oversight.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CW reports advisory board and lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, Eli-Lilly, Gilead, GSK, and MSD.CB and JS are employees of MicroDiscovery GmbH, Berlin, Germany.MB is an employee of Bayer AG, Wuppertal, Germany.FK is an employee of Bayer AG, Berlin, Germany.TV was a full-time employee of Bayer AG, Berlin, Germany at the time the study was performed and own shares in Bayer AG. TV is now an employee of Boehringer Ingelheim Pharma GmbH & Co. KG.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}